Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia: a 24-week follow-up study
Sign Up to like & getrecommendations! Published in 2018 at "International Clinical Psychopharmacology"
DOI: 10.1097/yic.0000000000000208
Abstract: Aripiprazole is a second-generation antipsychotics, acting as a partial dopamine D2 receptor agonist. Previous studies on aripiprazole for tardive dyskinesia (TD) treatment were limited and inconclusive. This study was aimed to examine the effectiveness of… read more here.
Keywords: week; treatment; psychotic patients; study ... See more keywords